AMCLAV-625

AMCLAV-625: Powerful Antimicrobial Solution

At Amparo Health Care, we are committed to providing cutting-edge healthcare solutions that address challenging infections with precision and efficacy. Introducing AMCLAV-625, a trusted combination of Amoxycillin 500 mg and Clavulanic Acid, formulated to combat resistant pathogens effectively.
AMCLAV-625 is a reliable choice for tackling a wide spectrum of infections, offering a remarkable success rate across various conditions:

Pneumonia: Achieves a success rate of 94%, ensuring rapid recovery in respiratory infections.

Tonsillitis and Sinusitis: Demonstrates high efficacy with cure rates of 89% and 90% respectively.

Urinary Tract Infections (UTI): Delivers an impressive 95% cure rate, outperforming many oral cephalosporins.

AMCLAV-625’s robust formulation, combining the bactericidal power of amoxicillin with the beta-lactamase inhibition of clavulanic acid, ensures exceptional effectiveness even in challenging cases. Choose AMCLAV-625 for its proven performance, safety, and reliability in treating bacterial infections. At Amparo Health Care, we aim to set new benchmarks in antimicrobial therapy, empowering healthcare providers and enhancing patient outcomes.